Nektar Therapeutics (NASDAQ:NKTR) Director Christopher A. Kuebler sold 30,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $58.66, for a total value of $1,759,800.00. Following the completion of the transaction, the director now directly owns 70,500 shares of the company’s stock, valued at $4,135,530. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up $0.98 during mid-day trading on Thursday, reaching $69.88. The company’s stock had a trading volume of 2,454,666 shares, compared to its average volume of 2,818,646. The stock has a market capitalization of $11,000.00, a P/E ratio of -98.42 and a beta of 1.81. The company has a quick ratio of 3.99, a current ratio of 4.14 and a debt-to-equity ratio of 2.91. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $73.95.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.16. The company had revenue of $152.90 million for the quarter, compared to the consensus estimate of $126.50 million. Nektar Therapeutics had a return on equity of 557.76% and a net margin of 39.80%. Nektar Therapeutics’s revenue for the quarter was up 321.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.32) earnings per share. equities research analysts anticipate that Nektar Therapeutics will post -0.75 EPS for the current year.
Several research analysts have recently commented on NKTR shares. Mizuho started coverage on Nektar Therapeutics in a research report on Tuesday, September 26th. They set a “buy” rating and a $30.00 target price on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $80.00 target price (up from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday. Canaccord Genuity Group upped their target price on Nektar Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, November 15th. Roth Capital set a $45.00 target price on Nektar Therapeutics and gave the company a “buy” rating in a research report on Monday, November 13th. Finally, JPMorgan Chase & Co. reissued a “buy” rating and issued a $44.00 price objective on shares of Nektar Therapeutics in a report on Monday, November 13th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $38.08.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NKTR. Janus Henderson Group PLC purchased a new position in shares of Nektar Therapeutics in the second quarter valued at approximately $34,661,000. PointState Capital LP lifted its position in shares of Nektar Therapeutics by 281.7% in the second quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock valued at $33,841,000 after acquiring an additional 1,277,500 shares in the last quarter. Rubric Capital Management LP purchased a new position in shares of Nektar Therapeutics in the third quarter valued at approximately $23,924,000. State Street Corp lifted its position in shares of Nektar Therapeutics by 11.3% in the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after acquiring an additional 447,023 shares in the last quarter. Finally, Numeric Investors LLC lifted its position in shares of Nektar Therapeutics by 2,111.5% in the second quarter. Numeric Investors LLC now owns 440,729 shares of the biopharmaceutical company’s stock valued at $8,616,000 after acquiring an additional 420,800 shares in the last quarter. Institutional investors and hedge funds own 96.01% of the company’s stock.
WARNING: “Christopher A. Kuebler Sells 30,000 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/11/christopher-a-kuebler-sells-30000-shares-of-nektar-therapeutics-nktr-stock.html.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.